

Valerio Rosato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4111798/publications.pdf>

Version: 2024-02-01

32
papers

1,055
citations

687220

13
h-index

434063

31
g-index

34
all docs

34
docs citations

34
times ranked

2205
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	447
2	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
3	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <i>PLoS ONE</i> , 2017, 12, e0178473.	1.1	79
4	Epidemiology and Natural History of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 167-174.	0.4	52
5	Non alcoholic fatty liver disease and eNOS dysfunction in humans. <i>BMC Gastroenterology</i> , 2017, 17, 35.	0.8	45
6	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	1.4	38
7	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	1.7	34
8	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	0.6	33
9	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
10	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 159-166.	0.4	30
11	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	1.9	28
12	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. <i>BMC Gastroenterology</i> , 2014, 14, 31.	0.8	24
13	Pharmacotherapy of alcoholic liver disease in clinical practice. <i>International Journal of Clinical Practice</i> , 2016, 70, 119-131.	0.8	24
14	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. <i>Infection</i> , 2018, 46, 231-238.	2.3	13
15	Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study. <i>Respiratory Physiology and Neurobiology</i> , 2018, 255, 7-10.	0.7	11
16	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	1.0	10
17	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. <i>Viruses</i> , 2022, 14, 1096.	1.5	9
18	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. <i>Hepatitis Monthly</i> , 2015, 15, e18640.	0.1	7

#	ARTICLE	IF	CITATIONS
19	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609.	1.3	7
20	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. <i>BMC Research Notes</i> , 2014, 7, 59.	0.6	6
21	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
22	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. <i>Life</i> , 2021, 11, 17.	1.1	6
23	Factors Enhancing Treatment of Hepatitis C Virus—Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255.	0.2	5
24	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 306-316.	0.4	4
25	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-332.	0.6	3
26	Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate—a pilot study. <i>Internal and Emergency Medicine</i> , 2018, 13, 901-906.	1.0	3
27	Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. <i>Biology</i> , 2022, 11, 805.	1.3	2
28	Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. <i>Biology</i> , 2022, 11, 800.	1.3	2
29	Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD. <i>Digestive and Liver Disease</i> , 2019, 51, e27-e28.	0.4	1
30	FRI-326-Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles. <i>Journal of Hepatology</i> , 2019, 70, e539.	1.8	0
31	Unusual liver-related heart injury. <i>JGH Open</i> , 2020, 4, 1240-1241.	0.7	0
32	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-32.	0.6	0